Drug Target Review

APRIL 7, 2025

Susceptibility or risk biomarkers can detect the likelihood of a patient developing a disease or medical condition, which is crucial for treatments that are most effective before the onset of symptoms. A biomarker is a measurable indicator of a biological process, disease state, or response to a treatment.

Clinical Development 69

Clinical Development Clinical Trials Clinical Pharmacology Trials 69

Drug Discovery Today

APRIL 26, 2020

To mark the 30th Anniversary of World Haemophilia Day, Sobi have released the 2020 Haemophilia Index which examines the quality of life for people with haemophilia in Europe, including the UK and the reach of humanitarian aid across the globe.

Treatment 100

Treatment 100

The Pharma Data

NOVEMBER 1, 2020

Vancouver-based Algernon Pharmaceuticals plans to conduct a late-stage study to evaluate an orally delivered drug, NP-120 (ifenprodil), as a COVID-19 treatment. The drug was originally developed in the 1990s by Sanofi to treat peripheral circulatory disorders and it is still used in generic form in Japan.

Pharmaceuticals 98

Pharmaceuticals Treatment Research Drugs 98

SCIENMAG: Medicine & Health

JULY 5, 2023

But a study published by The BMJ today finds that less than half of approved first indications for new drugs in the US and Europe between 2011 and 2020 add substantial therapeutic value over existing treatments […]

Treatment 67

Treatment Drugs Disease 67

The Pharma Data

JANUARY 20, 2021

a medical device company focused on the development and commercialization of treatments focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), today announced its company highlights for 2020 which have exceeded revenue targets. . DOYLESTOWN, Pa. ,

Production 52

Production Treatment Licensing Licensing 52

National Institute on Drug Abuse: Nora's Blog

MARCH 6, 2025

Advancing reduction of drug use as an endpoint in addiction treatment trials astewart Thu, 03/06/2025 - 09:59 Nora's Blog March 18, 2025 Image Getty Images/ SolStock This blog was also published in the American Society of Addiction Medicine (ASAM) Weekly on March 18, 2025.&

Treatment 69

Treatment Trials Clinical Trials Drugs 69

The Pharma Data

JANUARY 12, 2021

(NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2020 revenue. million to $48.9 About Inari Medical, Inc. Inari Medical, Inc.

FDA 52

FDA Treatment Production Disease 52

Eye on FDA

AUGUST 18, 2020

But it is not likely to surprise anyone that the first half of 2020 has caused not only an increase in communication from FDA, but a focus as well. Approvals – There were 54 press statements regarding approvals so far in 2020, comparing to 42 approvals announced in 2019.

FDA 61

FDA Production Drugs Therapies 61

Broad Institute

JUNE 18, 2024

By Allessandra DiCorato June 18, 2024 Credit: Jon Arizti-Sanz SHINE, a rapid diagnostic test developed by Pardis Sabeti's lab in 2020, uses paper strips and CRISPR enzymes to identify specific sequences of viral RNA in samples.

Virus 144

Virus RNA Laboratories Medical Schools 144

The Pharma Data

JANUARY 12, 2021

Preliminary revenue for the fourth quarter of 2020 is expected to be approximately $40.6 Preliminary revenue for the full year 2020 is expected to be approximately $125.4 2020 was a transformational year for Vapotherm. Preliminary revenue for the full year 2020 is expected to be approximately $125.4

Therapies 52

Therapies Production Marketing Regulations 52

Drug Target Review

OCTOBER 5, 2023

This innovative approach involves the extraction of a patient’s own stem cells from either their bone marrow or blood , followed by a course of chemotherapy and antibody treatment. The research team identified 231 individuals diagnosed with relapsing-remitting MS, with 174 of them having undergone aHSCT treatment before the year 2020.

Therapies 116

Therapies Treatment Clinical Trials Disease 116

The Pharma Data

MAY 16, 2021

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Merck’s Keytruda (pembrolizumab) for National Health Service use as first-line treatment for adults with untreated metastatic colorectal cancers with high levels of microsatellite instability or DNA mismatch repair deficiency. billion in 2020.

Treatment 52

Treatment DNA Drugs 52

Drug Target Review

SEPTEMBER 21, 2023

The findings supported the possibility put forward by Cotton et al (2016) concerning the chance of repurposing these drugs for adulticidal treatment. The available treatment for that is minor surgery -to remove the nodules. With accessible and effective treatments, this is feasible. doi: 10.1002/14651858.CD011146.pub2.

Drugs 105

Drugs Treatment Disease Research 105

The Pharma Data

FEBRUARY 4, 2021

3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. AbbVie hosted an Immunology Strategic Update event on December 14, 2020 for members of the investment community. NORTH CHICAGO, Ill., Gonzalez , chairman and chief executive officer, AbbVie.

Production 52

Production Clinical Trials International Small Molecule 52

The Pharma Data

FEBRUARY 25, 2021

Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. There were no treatment emergent serious adverse events observed in any AGN-190584 treated participants. The most common treatment emergent non-serious adverse events occurring at a frequency of ?5%

Treatment 52

Treatment Drugs Disease Production 52

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

The Pharma Data

JANUARY 14, 2021

Department of Health and Human Services’ (HHS) decision to effectively remove the “X-waiver” requirement for physicians, expanding their ability to utilize medication-assisted treatment (MAT) for patients struggling with opioid use disorder (OUD). Added Dr. Rosenberg, “This is a great day for our patients.

Treatment 52

Treatment Licensing Licensing Hospitals 52

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Therapies 119

Therapies FDA FDA Approval Treatment 119

The Pharma Data

APRIL 15, 2022

The top protein neutralized the virus with similar or greater potency than antibody treatments with Emergency Use Authorization status from the U.S. This work was originally reported in 2020 in the journal Science. Just last month, the FDA paused several monoclonal antibody treatments, for example, due to their failure against the BA.2

Treatment 52

Treatment Virus Laboratories Engineering 52

The Pharma Data

JANUARY 13, 2021

Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. Harpoon has four drug product candidates in clinical development for the treatment of solid and hematologic malignancies based on its proprietary TriTAC platform. “I About the Phase 1/2 Trial for HPN217.

Treatment 52

Treatment FDA Clinical Trials Trials 52

The Pharma Data

MARCH 30, 2021

2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. .

Treatment 52

Treatment FDA Doctors FDA Approval 52

Drug Target Review

JULY 1, 2024

As a non-opioid, SRP-001 also eliminates abuse potential, positioning it as a safer and effective drug candidate for the treatment of acute and neuropathic pain and migraine headache. How does SRP-001’s safety profile, especially concerning hepatotoxicity and nephrotoxicity, compare to other common pain medications?

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

Chemical Biology and Drug Design

OCTOBER 2, 2023

Abstract Despite the successful reduction in the malaria health burden in recent years, it continues to remain a significant global health problem mainly because of the emerging resistance to first-line treatments.

Research 100

Research Treatment 100

The Pharma Data

FEBRUARY 24, 2022

Allergan, an AbbVie (NYSE: ABBV) company, today announced new data to be presented from Allergan’s leading portfolio of eye care treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting being held in Nashville, TN and virtually from March 3-6. DURYSTA ® Consumer Indications and Usage and Important Safety Information.

Treatment 52

Treatment FDA Approval FDA Disease 52

The Pharma Data

OCTOBER 14, 2021

COBRA study subgroups results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). There’s historically limited clinical safety data for babies who are breastfed by maters witnessing treatment for MS including during the gestation period. NYSE and TASE TEVA) andSt.

Treatment 52

Treatment Pharmaceuticals Hospitals Production 52

The Pharma Data

APRIL 7, 2022

It may also limit coverage for any future approved treatment in the class. When additional data from this new class of treatments become available, Biogen urges CMS to reconsider today’s decision for all FDA-approved amyloid-beta targeting therapies. ADUHELM is indicated for the treatment of Alzheimer’s disease.

Treatment 52

Treatment Therapies Disease FDA Approval 52

The Pharma Data

JANUARY 19, 2021

NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Friday, February 5, 2021 , before the U.S. TARRYTOWN, N.Y. , 19, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. financial markets open.

FDA Approval 52

FDA Approval Laboratories Disease Pharmaceuticals 52

Drug Target Review

SEPTEMBER 22, 2023

8 Furthermore, the absence of immune, mesenchymal, or endothelial cells limits the applicability of organoids for the assessment of certain therapies, such as immuno-oncology treatments or drug metabolism studies where more complex models are needed. Elsevier; 2020. 2020 Oct 7;21(10):571–84. 2020 Jun 8;4(9):863–74.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MARCH 26, 2021

Despite continuous innovations in the treatment landscape, unmet needs remain. Overall, the number of treatment-emergent adverse events reported was similar between the ponesimod and teriflunomide treated groups, and the majority were mild/moderate and did not warrant treatment discontinuation. vs. 9.4%), nasopharyngitis (19.3%

Treatment 52

Treatment Pharmaceutical Companies Pharmaceuticals FDA Approval 52

Drug Target Review

SEPTEMBER 25, 2024

4 Another related and well described non-oncogene resistance mechanism is the histological transformation of EGFR-mutated non-small cell lung cancer (NSCLC) to small-cell lung cancer upon treatment with an EGFR inhibitor. Notably, TT125-802 stabilised disease and prevented further outgrowth of tumours resistant to standard-of-care treatment.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

DS in Pharmatics

JUNE 10, 2023

On April 12, 2023, BeNeLuxA1 announced that negotiations failed to secure reimbursement for Libmeldy, a gene therapy developed by Orchard Therapeutics for the treatment of metachromatic leukodystrophy, on grounds of price. In the UK, an initial application to NICE was rejected as well back in 2020. This is a huge […]

Marketing 66

Marketing Therapies Treatment 66

The Pharma Data

JANUARY 10, 2021

SH ) submitted its pivotal phase III clinical trial application (IND) of national class I innovative drug Chiauranib to NMPA, for the treatment of Small Cell Lung Cancer (SCLC) as a single agent for the patients after 2nd-line systemic chemotherapy and recurrence afterwards. (Chipscreen Biosciences, Stock Symbol: 688321.SH

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

SugarCone Biotech

MARCH 24, 2025

Other mechanisms that cancer cells use to escape from TCE treatment are less expected. This provides ample flexibility to optimize the treatment modality to attack specific cancers. CD58 is a protein that interacts with the CD2 protein that is expressed on T cells to upregulate T cell activation. doi: 10.1073/pnas.1716266115

Immune Response 67

Immune Response Therapies Treatment Disease 67

The Pharma Data

MAY 2, 2022

The companies expect to complete submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression anticipated in the first half of 2023. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD). Sage Therapeutics, Inc.

Treatment 52

Treatment Clinical Pharmacology Drugs Clinical Development 52

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Mr. Ho was an inductee into the McMaster University Alumni Gallery in 2020 and currently serves as a member of their Dean’s Advisory Board for the Faculty of Science. Cells 9(40):800 (2020). Cell Mol Immunol 17:925-939 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105

Broad Institute

JUNE 14, 2024

But when postdoctoral researcher and study first author Sean Misek joined Boehm’s and Beroukhim’s labs in 2020, he wanted to know how germline genetic variants — which are inherited and in all cells throughout the body — influence how tumors respond to treatment.

Drugs 145

Drugs RNA DNA Research 145